Company profile
Helix BioPharma Corp.
OTC: HBPCF · Healthcare · Biotechnology
Canadian filerHQ Toronto, ONReports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH 60DQ —GM —SS 52
v0.1 · 35/100 weight · pillars only
↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.6M
Employees
7
as of 2026-08-14
Market cap
$130.6M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$00 CAD2025
Net income-$3.6M-5.0M CAD2025
Operating income-$3.6M-5.0M CAD2025
Total assets$13.5M18.7M CAD2025
Liabilities$2.3M3.2M CAD2025
Equity$11.2M15.5M CAD2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Helix BioPharma Corp.’s revenue?
Helix BioPharma Corp. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
TuHURA Biosciences, Inc.36DSpruce Biosciences, Inc.40DAardvark Therapeutics, Inc. Common Stock40DVivani Medical, Inc.33DFractyl Health, Inc.28DParabilis Medicines, Inc.——Key facts
CEOThomas Mehrling
SectorHealthcare
IndustryBiotechnology
HeadquartersToronto, ON
ExchangeOTC: HBPCF
Employees7
IPO date2009-11-27
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.